



# TEST MENU

## 1. Urine Specimen Validity by EIA

Creatinine, pH, Specific Gravity, Oxidants

## 2. Urine Drug Screen by EIA

Amphetamine	Cocaine	Opiates
Barbiturates	Ecstasy	Oxycodone
Benzodiazepines	Ethyl Glucuronide	Phencyclidine
Cannabinoids		

## 3. Urine Toxicology Confirmation by LC-MS/MS

6-MAM	Gabapentin	Norfentanyl
7-Aminoclonazepam	Hydrocodone	Norhydrocodone
alpha-Hydroxyalprazolam	Hydromorphone	Normeperidine
Alprazolam	Imipramine	Noroxycodone
Amitriptyline	JWH-018 Metabolite	Nortriptyline
Amphetamine	JWH-073 Metabolite	Oxazepam
Benzoyllecgonine	Ketamine	Oxycodone
Buprenorphine	Lorazepam	Oxymorphone
Butalbital	MDMA	PCP
Carisoprodol	Meperidine	Phentermine
Clonazepam	Meprobamate	Pregabalin
Codeine	Methadone	Propoxyphene
Cotinine	Methamphetamine	Tapentadol
Desipramine	Methylphenidate	Temazepam
Diazepam	Morphine	THCA
EDDP	Norbuprenorphine	Tramadol
Fentanyl	Nordiazepam	Zolpidem

EIA is Enzyme-Immunoassay. This screening assay provides a preliminary qualitative result and must be confirmed by a more specific quantitative analytical method such as Gas Chromatography Mass Spectrometry (GC/MS) or Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS). Clinical and professional judgment should be applied to any drug of abuse test result, particularly when preliminary results are used. Dax Laboratories, has developed the test methodology and determined its performance characteristics. The test methodology is for clinical purposes only and has not been cleared or approved by the FDA. Analytical testing has been conducted per Dax Laboratories, standard operating procedures under regulation of the Clinical Laboratory Improvement Act of 1988 (CLIA) and is COLA accredited to perform highly complex tests such as LC-MS/MS.